152 related articles for article (PubMed ID: 30323967)
1. The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
Hu WT; Yeh CC; Liu SY; Huang MC; Lai IR
Am J Cancer Res; 2018; 8(9):1739-1751. PubMed ID: 30323967
[TBL] [Abstract][Full Text] [Related]
2. Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Liu SY; Shun CT; Hung KY; Juan HF; Hsu CL; Huang MC; Lai IR
Oncotarget; 2016 Mar; 7(10):11251-62. PubMed ID: 26848976
[TBL] [Abstract][Full Text] [Related]
3. Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
Sun Z; Xue H; Wei Y; Wang C; Yu R; Wang C; Wang S; Xu J; Qian M; Meng Q; Li G
Clin Sci (Lond); 2019 May; 133(10):1167-1184. PubMed ID: 31076460
[TBL] [Abstract][Full Text] [Related]
4. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
[TBL] [Abstract][Full Text] [Related]
5. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Zhou X; Xu Y; Yin D; Zhao F; Hao Z; Zhong Y; Zhang J; Zhang B; Yin X
Biomed Pharmacother; 2020 Nov; 131():110764. PubMed ID: 33152927
[TBL] [Abstract][Full Text] [Related]
7. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Ho WL; Chou CH; Jeng YM; Lu MY; Yang YL; Jou ST; Lin DT; Chang HH; Lin KH; Hsu WM; Huang MC
Oncotarget; 2014 Dec; 5(23):12247-59. PubMed ID: 25362349
[TBL] [Abstract][Full Text] [Related]
8. Expression of GALNT2 in human extravillous trophoblasts and its suppressive role in trophoblast invasion.
Liao WC; Chen CH; Liu CH; Huang MJ; Chen CW; Hung JS; Chou CH; Chen CH; Che MI; Chang HM; Lan CT; Huang HC; Tseng GF; Shyu MK; Huang MC
Placenta; 2012 Dec; 33(12):1005-11. PubMed ID: 23117232
[TBL] [Abstract][Full Text] [Related]
9. GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL.
Liao YY; Chuang YT; Lin HY; Lin NY; Hsu TW; Hsieh SC; Chen ST; Hung JS; Yang HJ; Liang JT; Huang MC; Huang J
Mol Oncol; 2023 Jan; 17(1):119-133. PubMed ID: 36409270
[TBL] [Abstract][Full Text] [Related]
10. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
[TBL] [Abstract][Full Text] [Related]
11. The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer.
Hu Q; Tian T; Leng Y; Tang Y; Chen S; Lv Y; Liang J; Liu Y; Liu T; Shen L; Dong X
Cell Mol Biol Lett; 2022 Sep; 27(1):71. PubMed ID: 36058918
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Rojo F; Tabernero J; Albanell J; Van Cutsem E; Ohtsu A; Doi T; Koizumi W; Shirao K; Takiuchi H; Ramon y Cajal S; Baselga J
J Clin Oncol; 2006 Sep; 24(26):4309-16. PubMed ID: 16963731
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.
Huang MJ; Hu RH; Chou CH; Hsu CL; Liu YW; Huang J; Hung JS; Lai IR; Juan HF; Yu SL; Wu YM; Huang MC
Oncotarget; 2015 Mar; 6(8):5650-65. PubMed ID: 25730904
[TBL] [Abstract][Full Text] [Related]
14. PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells.
Kim TW; Ryu HH; Li SY; Li CH; Lim SH; Jang WY; Jung S
J Neurosurg; 2017 Jun; 126(6):1829-1838. PubMed ID: 27540907
[TBL] [Abstract][Full Text] [Related]
15. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
16. O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer.
Zhou L; Wu H; Bai X; Min S; Zhang J; Li C
Pathol Oncol Res; 2022; 28():1610554. PubMed ID: 36110252
[TBL] [Abstract][Full Text] [Related]
17. Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function.
Zilmer M; Edmondson AC; Khetarpal SA; Alesi V; Zaki MS; Rostasy K; Madsen CG; Lepri FR; Sinibaldi L; Cusmai R; Novelli A; Issa MY; Fenger CD; Abou Jamra R; Reutter H; Briuglia S; Agolini E; Hansen L; Petäjä-Repo UE; Hintze J; Raymond KM; Liedtke K; Stanley V; Musaev D; Gleeson JG; Vitali C; O'Brien WT; Gardella E; Rubboli G; Rader DJ; Schjoldager KT; Møller RS
Brain; 2020 Apr; 143(4):1114-1126. PubMed ID: 32293671
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
[TBL] [Abstract][Full Text] [Related]
19. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells.
Zhen Y; Guanghui L; Xiefu Z
Cancer Gene Ther; 2014 Nov; 21(11):491-7. PubMed ID: 25394504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
